April 13, 2021 -- Jaguar Gene Therapy has closed $139 million in funding to advance its preclinical pipeline of adeno-associated virus 9 (AAV9)-based gene therapies.
The company's pipeline includes three agents: JAG101, a gene therapy treatment in development for galactosemia; JAG201, a gene therapy treatment in development for a specific genetic cause of autism spectrum disorder; and JAG301, a gene therapy treatment in development for type 1 diabetes.
Jaguar's subsidiary, Axovia Therapeutics, is also advancing AXV101, a gene therapy treatment for subset of Bardet-Biedl syndrome (BBS), BBS1.
The series B funding was co-led by Eli Lilly and Deerfield Management. Additional investors include ARCH Venture Fund XI, the Goldman Sachs fund, and Nolan Capital.